Rifamycin L 105SV en es it fr

Rifamycin L 105SV Brand names, Rifamycin L 105SV Analogs

Rifamycin L 105SV Brand Names Mixture

  • Sans-Acne Solution (Alcohol Anhydrous + Erythromycin)
  • Staticin Lot (Alcohol Anhydrous + Erythromycin + Laureth 4)
  • T-Stat Lot (Alcohol Anhydrous + Erythromycin)
  • T-Stat Pad-Lot (Alcohol Anhydrous + Erythromycin)

Rifamycin L 105SV Chemical_Formula


Rifamycin L 105SV RX_link


Rifamycin L 105SV fda sheet

Rifamycin_L_105SV FDA

Rifamycin L 105SV msds (material safety sheet)

Rifamycin L 105SV Synthesis Reference

No information avaliable

Rifamycin L 105SV Molecular Weight

272.365 g/mol

Rifamycin L 105SV Melting Point

206.5-207 oC

Rifamycin L 105SV H2O Solubility

Soluble (5510 mg/L)

Rifamycin L 105SV State


Rifamycin L 105SV LogP


Rifamycin L 105SV Dosage Forms

Tablets (white, capsule-shaped, for oral administration)

Rifamycin L 105SV Indication

For the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.

Rifamycin L 105SV Pharmacology

Sotalol is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the β-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, sotalol inhibits the inward potassium ion channels of the heart. In so doing, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction. Because of these actions on the cardiac action potential, it is also considered a class III antiarrhythmic agent. The beta-blocking effect of sotalol is non-cardioselective, half maximal at about 80mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class Ieffects are seen only at daily doses of 160 mg and above.

Rifamycin L 105SV Absorption

In healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.

Rifamycin L 105SV side effects and Toxicity

The most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.

Rifamycin L 105SV Patient Information

Rifamycin L 105SV Organisms Affected

Humans and other mammals